SALUTENSIN-DEMI
LOE ApproachingNDAORALTABLET
Approved
Jun 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SALUTENSIN-DEMI is an oral tablet small-molecule drug approved in 1960 by Takeda. The mechanism of action and specific indications are not publicly detailed in available data. This is a legacy NDA product with significant historical market presence.
LOE Approaching
Product is in decline phase with minimal commercial expansion; team sizes likely reduced or consolidated into legacy portfolio management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings indicate this is a declining legacy product with minimal active hiring. Career opportunities are limited to maintenance, compliance, and portfolio management roles rather than strategic growth positions.
Legacy Product ManagerCompliance Officer
Worked on SALUTENSIN-DEMI at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.